Responding to requests for administrative help with Parkinson’s patients, the Parkinson's Disease Foundation will sponsor an attorney-led webinar at 1 p.m. (EST) Tuesday, Nov. 8, for families, friends and care givers.
The Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC) recently released new recommendations for the dosing schedule of Trumenba (Meningococcal Group B) vaccinations.
Dr. Alan Schwartzstein, vice speaker of the American Academy of Family Physicians (AAFP) Congress of Delegates, recently released a blog post on the AAFP website describing the importance of combatting opioid addiction.
PatientPoint recently launched a new mobile app that will enable physicians to improve how they practice medicine, in addition to offering patients more information to benefit their overall experience.
Amgen has announced a phase-three study analyzing how XGEVA competes with zoledronic acid when it comes to meeting the primary endpoint of non-inferiority in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma.
Johnson & Johnson Innovation LLC (JJI) announced this week that it has created the Center for Device Innovation at Texas Medical Center as a collaboration between JJI and TMC to accelerate the development of medical devices.
The University of Michigan Comprehensive Cancer Center and Tempus, a health technology company dedicated to personalizing cancer care, recently partnered to offer the Michigan Oncology Sequencing Center (MI-ONCOSEQ) panel to health care providers and patients in the U.S.
Health Center Partners, a top consortium of community health centers, recently acquired over $1.3 million from the U.S. Department of Health and Human Services (HHS) to fund health information technology improvements.
Boehringer Ingelheim and ViraTherapeutics recently formed a long-term partnership to create a next-generation oncolytic virus therapy platform and evaluate a top candidate Vesicular Stomatitis Virus (VSV) glycoprotein (GP).
Chembio Diagnostics Inc., a leader in point-of-care (POC) diagnostic tests for infectious diseases, recently received a contract from the Centers for Disease Control and Prevention (CDC) for surveillance diagnostic assays for Zika, dengue and chikungunya.